Trial Profile
A Single-centre Study Evaluating the Safety of ViscoGel and Its Safety and Efficacy as an Adjuvant in Act-HIB Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Sep 2013
Price :
$35
*
At a glance
- Drugs Chitosan-based adjuvant (Primary) ; Hib vaccine conjugate
- Indications Haemophilus infections
- Focus Adverse reactions; Pharmacodynamics
- 15 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported ClinicalTrials.gov.
- 23 Apr 2012 New trial record